ISPOR News

ISPOR—The Professional Society for Health Economics and Outcomes Research announced today the recipients of its 2024 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards.

ISPOR announced the publication of a study that provides estimates of how the Centers for Medicare & Medicaid Services (CMS) may have determined initial price offers for the first 10 drugs selected for Medicare price negotiation. A prepublication version of the study was released online on the same day the CMS announced it reached agreements for lower drug prices.

ISPOR—The Professional Society for Health Economics and Outcomes Research announced the plenary sessions and speakers for ISPOR Europe 2024. The conference is the leading European conference for health economics and outcomes research (HEOR) and is scheduled for 17-20 November in Barcelona, Spain with the theme, “Generating Evidence Toward Health and Well-Being.”

ISPOR announced its new Strategic Plan 2030 that presents a bold new vision for the Society and the field of health economics and outcomes research (HEOR).

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.

ISPOR—The Professional Society for Health Economics and Outcomes Research announced the results of its recent elections. The Society’s membership selected its new president-elect and 4 new board members. The 2024-2025 board will assume office on July 1.

ISPOR—The Professional Society for Health Economics and Outcomes Research announced today the publication of a report from the ISPOR Biosimilars Special Interest Group highlighting the need for clearer guidance on when and how to conduct health technology assessments (HTAs) for biosimilars.

ISPOR announced the sessions and speakers for its Patient-Centered Research Summit 2024. The Summit is scheduled to be held May 5 in Atlanta, GA, USA and is co-located with the Society’s annual international conference, ISPOR 2024.